Conferences - Results from #8880

ASCO GU 2016 Active Surveillance: How to Measure, Manage, and Improve. - Poster Session Highlights January 8, 2016

ASCO GU 2016 Urologists’ experiences with treatment of castration-resistant prostate cancer. - Poster Session Highlights January 8, 2016

ASCO GU 2016 Small cell carcinoma of the bladder: Comparison of survival in various treatment modalities at Fox Chase Cancer Center (FCCC) from 1995 to 2015. - Poster Session Highlights January 8, 2016

ASCO GU 2016 After the 2012 USPSTF Recommendation on Prostate Cancer Screening, Higher Gleason Grades and More Positive Cores January 8, 2016

ASCO GU 2016 Management of metastatic prostate cancer patients in first line: Audit of real-life practices - Poster Session Highlights January 8, 2016

ASCO GU 2016 Point/Counterpoint: Novel Checkpoint Blockade Strategies in Non-Muscle Invasive Bladder Cancer— Medical Oncologist Perspective - Session Highlights January 8, 2016

ASCO GU 2016 State of Predictive Biomarkers and Response to Immunotherapy in Advanced Disease - Session Highlights January 8, 2016

ASCO GU 2016 Urothelial Carcinomas: Year in Review - Session Highlights January 8, 2016

ASCO GU 2016 Novel Checkpoint Blockade Strategies in Non-Muscle Invasive Bladder Cancer: Urologist Perspective - Session Highlights January 8, 2016

ASCO GU 2016 Abstract 355: IMvigor 210, a phase 2 trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma - Session Highlights January 8, 2016

ASCO GU 2016 Best of Journals: Prostate Cancer Medical Oncology - Session Highlights January 8, 2016

ASCO GU 2016 Best of Journals: Prostate Cancer Surgical Oncology - Session Highlights January 8, 2016

ASCO GU 2016 Best of Journals: Prostate Cancer Radiation Oncology - Session Highlights January 8, 2016

ASCO GU 2016 Changes in the Treatment of Hormone-Naïve Metastatic Prostate Cancer - Session Highlights January 8, 2016

ASCO GU 2016 Evaluating PSA nadir drift in high-risk and metastatic prostate cancer. - Poster Session Highlights January 8, 2016

ASCO GU 2016 Prostate Cancer: Year in Review - Session Highlights January 8, 2016

ASCO GU 2016 Best Use of Approved Therapies for Bone Metastases - Session Highlights January 8, 2016

ASCO GU 2016 Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride (Ra-223) and abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases January 7, 2016

ASCO GU 2016 – Oral Abstract Session: NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following (RP) and an elevated PSA. - Session Highl January 7, 2016

ASCO GU 2016 Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: Survival results from STAMPEDE (NCT00268476). – Poster Session Highlights January 7, 2016

Page 445 of 525